Drug checking service (SAS)

Report on samples analyzed in April and May 2022

In addition to continuing our collaboration with Spectre de Rue, Centre SIDA-Secours, and Maison Benoit-Labre, in May, we started offering our service in collaboration with Dopamine next to their supervised consumption site. We have also offered drug checking at several events and raves (if you or someone you know would like to have us at their event, contact us :) )

Here we present our report and data from the analyses we performed in April and May 2022 with three types of analytical technologies: colorimetric reagents, fentanyl and benzodiazepine detection strips, and infrared spectrometry (FT-IR).

Due to the limitations of our hours and locations of operation, as well as our technologies, the results of our report likely do not represent the true composition of drugs in the unregulated Montreal market.

Key points

• During this period, we analyzed 83 samples.
• We tested 24 samples purchased as MDMA. Instead of MDMA, 10 of these samples contained MDA, 1 sample contained methamphetamine, and 1 sample contained N-ethylpentylone.
• One sample, purchased as a Dilaudid (hydromorphone) tablet, was found to contain isotonitazene, a synthetic opioid similar in potency to fentanyl, which does not react to fentanyl test strips.

Download the complete report here.

We are interested in receiving your questions, comments and suggestions to improve the presentation of the analysis results. To do so, please contact the service coordinator at the following email address: analyse@grip-prevention.ca

We regularly add new dates of service to our website, so please check here or call or text us (438-887-8338) to find out when we are offering drug checking.